Literature DB >> 2366149

Human immunodeficiency virus neutralizing antibodies in sera from North Americans and Africans.

D A Katzenstein1, L K Vujcic, A Latif, R Boulos, N A Halsey, T C Quinn, S C Rastogi, G V Quinnan.   

Abstract

Neutralizing antibodies (NAs) against four isolates of human immunodeficiency virus type 1 (HIV-1) were assayed in HIV-1 antibody positive sera from the United States, Haiti, Zimbabwe, and Zaire. Overall, there were NAs detected in 95, 81, 60, and 73% of sera with reciprocal geometric mean titers (GMTs) of 626, 23, 10, and 20, respectively, against HIV-1MN, HIV-1IIIB, HIV-1RF, and HIV-1Z3. Sera from North America had significantly higher NA titers against HIV-1MN. In each country, the highest antibody titers observed were against the MN strain. Otherwise, sera from the U.S. neutralized most strongly HIV-1IIIB, sera from Zaire neutralized most strongly HIV-1Z3, and sera from Zimbabwe had equal titers against all three viruses. The differences between countries were reflected in analyses of NA titers of subgroups classified on the basis of clinical status, indicating that the differences were not likely to be related to differences in clinical status of the patients being tested. Some of this antigenic variation is reflective of known genetic diversity, while some is not. The results suggest that undefined preserved and variable regions containing neutralization epitope(s) exist. These data do not indicate a need to define antigenic subtypes of HIV-1 at present. The existence of conserved neutralization epitope(s) may indicate the potential for broad immunogenicity of appropriately selected vaccine antigens.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2366149

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  8 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

2.  Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.

Authors:  E J Park; L K Vujcic; R Anand; T S Theodore; G V Quinnan
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

3.  Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons.

Authors:  N L Haigwood; P L Nara; E Brooks; G A Van Nest; G Ott; K W Higgins; N Dunlop; C J Scandella; J W Eichberg; K S Steimer
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

Review 4.  DNA gene vaccination for HIV.

Authors:  J J Kim; D B Weiner
Journal:  Springer Semin Immunopathol       Date:  1997

5.  Concordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120.

Authors:  Maria Leavitt; Eun Ju Park; Igor A Sidorov; Dimiter S Dimitrov; Gerald V Quinnan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

6.  Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity.

Authors:  M E Goldman; J H Nunberg; J A O'Brien; J C Quintero; W A Schleif; K F Freund; S L Gaul; W S Saari; J S Wai; J M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

7.  Human immunodeficiency virus type 1 primary isolate neutralization resistance is associated with the syncytium-inducing phenotype and lower CD4 cell counts in subtype CRF01_AE-infected patients.

Authors:  Victoria R Polonis; Mark S de Souza; Janice M Darden; Somsak Chantakulkij; Thippawan Chuenchitra; Sorachai Nitayaphan; Arthur E Brown; Merlin L Robb; Deborah L Birx
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 nef quasispecies in pathological tissue.

Authors:  B M Blumberg; L G Epstein; Y Saito; D Chen; L R Sharer; R Anand
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.